Bioatla (BCAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Jun, 2026Executive summary
Annual Meeting scheduled for July 16, 2026, to be held virtually at 8:00 a.m. PST.
Proxy materials and annual report are available online, with options for paper or email copies upon request.
Stockholders can vote online, by phone, or during the virtual meeting using a unique control number.
Voting matters and shareholder proposals
Election of two Class III directors, Jay M. Short, Ph.D., and Edward Williams, for three-year terms expiring at the 2029 Annual Meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation for named executive officers.
Provision to transact any other business that may arise during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all three main proposals presented at the meeting.
Latest events from Bioatla
- Q2 2026 net income driven by $6.5M licensing revenue, but going concern risks persist.BCAB
Q2 2026 - Shareholders will vote on director elections, auditor ratification, and executive pay, all recommended for approval.BCAB
Proxy filing - Net loss narrowed, cash remains low, and strategic review continues amid going concern risks.BCAB
Q1 2026 - CAB platform delivers tumor-selective therapies with strong efficacy and safety in solid tumors.BCAB
Investor presentation - Net loss of $59.6M in 2025, cash runway through H1 2026, and a 70% workforce reduction amid strategic review.BCAB
Q4 2025 - Stockholders to vote on a merger and share conversion at a reconvened meeting on March 23, 2026.BCAB
Proxy Filing - FDA-aligned Phase 3 trial, milestone payment, and low cash highlight progress and risk.BCAB
Q3 2025 - Q3 2024 featured clinical progress, reduced losses, and a licensing deal extending cash runway to 2026.BCAB
Q3 2024 - Q1 2025 saw narrowed losses, strong clinical data, and a cash runway into 1H 2026 amid funding risks.BCAB
Q1 2025